<DOC>
	<DOCNO>NCT01979536</DOCNO>
	<brief_summary>This partially randomize phase II trial study well brentuximab vedotin crizotinib combination chemotherapy work treat patient newly diagnose stage II-IV anaplastic large cell lymphoma . Monoclonal antibody-drug conjugate , brentuximab vedotin , block cancer growth different way target certain cell . Crizotinib methotrexate may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . It yet know whether brentuximab vedotin combination chemotherapy effective crizotinib combination chemotherapy treat anaplastic large cell lymphoma .</brief_summary>
	<brief_title>Brentuximab Vedotin Crizotinib Combination Chemotherapy Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine tolerability brentuximab vedotin give combination standard chemotherapy ( anaplastic large cell lymphoma [ ALCL ] 99 ) determine tolerability crizotinib give combination chemotherapy ( ALCL99 ) . II . To estimate event free survival ( EFS ) Arm brentuximab vedotin ( BV ) Arm crizotinib ( CZ ) contrast historical control data . SECONDARY OBJECTIVES : I . To determine prognostic significance minimal disseminate disease ( MDD ) diagnosis minimal residual disease ( MRD ) measure real-time ( RT ) -polymerase chain reaction ( PCR ) peripheral blood . OUTLINE : Patients assign randomized 1 2 treatment arm . ARM BV : COURSE A ( COURSES 1 , 3 , AND 5 ) : Patients receive brentuximab vedotin intravenously ( IV ) 30 minute day 1 , dexamethasone orally ( PO ) twice daily ( BID ) IV day 1-5 , ifosfamide IV 60 minute day 1-5 , methotrexate IV 3 hour day 1 , cytarabine IV 1-30 minute every 12 hour 4 dos day 4 5 , etoposide IV 2 hour day 4 5 . COURSE B ( COURSES 2 , 4 , AND 6 ) : Patients receive brentuximab vedotin , dexamethasone , methotrexate Arm BV , Course A . Patients also receive cyclophosphamide IV 15-30 minute day 1-5 doxorubicin hydrochloride IV 1-15 minute day 4 5 . ARM CZ : COURSE A ( COURSES 1 , 3 , AND 5 ) : Patients receive crizotinib PO BID day 1-21 dexamethasone , ifosfamide , methotrexate , cytarabine , etoposide Arm BV , Course A . COURSE B ( COURSES 2 , 4 , AND 6 ) : Patients receive crizotinib Arm CZ , Course A dexamethasone , cyclophosphamide , methotrexate , doxorubicin hydrochloride Arm BV , Course B . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 , 6 , 9 , 12 , 18 , 24 , 36 , 48 , 60 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Newly diagnose patient histologically proven ALCL ( International Classification Diseases Oncology [ ICD0 ] code : 9714/3 ) Disease must cluster differentiation ( CD ) 30 positive Disease must anaplastic lymphoma kinase ( ALK ) positive ( defined local institutional standard ) Patients must stage II , III , IV disease Patients must life expectancy &gt; = 8 week Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 x upper limit normal ( ULN ) age ; purpose study , ULN ALT 45 U/L If lab abnormality think due lymphoma patient eligible dose adjustment make Shortening fraction &gt; = 27 % echocardiogram , Ejection fraction &gt; = 50 % radionuclide angiogram Patients history pulmonary dysfunction must evidence dyspnea rest , exercise intolerance due pulmonary insufficiency , pulse oximetry &gt; 92 % breathing room air unless current dysfunction due lymphoma case patient eligible Patients central nervous system ( CNS ) disease eligible Patients disease limit skin eligible , regardless widespread Patients stage I disease eligible Patients receive prior cytotoxic chemotherapy current diagnosis ALCL cancer diagnose previously eligible Previous steroid treatment and/or radiation treatment allow unless emergent management mediastinal mass ; emergent steroid treatment and/or radiation treatment stop protocol therapy initiate Intrathecal chemotherapy prior enrollment allow current diagnosis ALCL long adequate cerebrospinal fluid ( CSF ) obtain prior administration intrathecal chemotherapy subsequently demonstrate negative ALCL Female patient pregnant eligible ; pregnancy test must obtain girl post menarchal Lactating females eligible unless agree breastfeed infant Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration treatment 3 month stop treatment Patients Down syndrome eligible Patients immunodeficiency exist prior diagnosis primary immunodeficiency syndrome organ transplant recipient eligible Cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) substrates narrow therapeutic index : Patients chronically receive medication know metabolized CYP3A4 narrow therapeutic index include pimozide , aripiprazole , triazolam , ergotamine halofantrine eligible ; topical use medication ( applicable ) allow CYP3A4 inhibitor : patient chronically receive drug know potent CYP3A4 inhibitor within 7 day prior study enrollment , include limited ketoconazole , itraconazole , clarithromycin , erythromycin , ritonavir , indinavir , nelfinavir , saquinavir , delavirdine , nefazodone , diltiazem , verapamil , grapefruit juice eligible ; topical use medication ( applicable ) , e.g . 2 % ketoconazole cream , allow CYP3A4 inducer : patient chronically receive drug know potent CYP3A4 inducer within 12 day prior study enrollment , include limited carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , ritonavir , St. John 's wort eligible ; topical use medication ( applicable ) allow Patients know positive human immunodeficiency virus ( HIV ) eligible ; note : inclusion HIV positive patient consider later date Patients weigh &lt; 10 kg eligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>